Real-world experience of vedolizumab use in Colombian patients with inflammatory bowel disease-EXVEDOCOL.
Viviana ParraSandra CifuentesSandra AvendañoEnrique Ponce de LeónCristian FlorezGustavo ReyesFabian PuentesManuel BallesterosEdilberto NuñezFederico GómezJuan Ricardo MárquezPublished in: Gastroenterologia y hepatologia (2024)
High clinical remission rates and safety profile highlight VDZ as a valuable treatment option for IBD patients. Anti-TNF naïve patients may derive greater benefit from therapy. Studies with larger cohorts could confirm these findings.